Particle.news
Download on the App Store

Studies Link Medical Cannabis and Dispensary Openings to Sharp Drops in Opioid Prescribing

Analyses of millions of commercial insurance claims tie prescribing declines to practical access through dispensaries.

Overview

  • Two peer-reviewed papers from University of Georgia–led teams, in the American Journal of Health Economics and JAMA Health Forum, report associations between cannabis policy changes and lower opioid use.
  • States that legalized medical cannabis saw a 16% average reduction in the share of patients receiving opioid prescriptions.
  • Opening medical or recreational dispensaries corresponded with significant declines in multiple opioid measures, including prescribing rates, days supplied, and prescriptions per patient, with cancer populations specifically analyzed.
  • Reductions were consistent across sexes, ages, races and ethnicities, and socioeconomic groups, suggesting broad effects across patient subpopulations.
  • The studies use 2007–2020 commercial claims covering roughly 15–20 million enrollees annually, note small increases in NSAID prescribing, and caution that results are observational and should inform physician-guided pain management.